Jacqueline M Anderson1, Alvaro Cerda2, Mario H Hirata1, Alice C Rodrigues3, Egidio L Dorea4, Marcia M S Bernik4, Marcelo C Bertolami5, Andre A Faludi5, Rosario D C Hirata6. 1. School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, B17, Sao Paulo 05508-000, SP, Brazil. 2. School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, B17, Sao Paulo 05508-000, SP, Brazil; Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de la Frontera, Temuco, Chile. 3. Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil. 4. University Hospital, University of Sao Paulo, Sao Paulo, SP, Brazil. 5. Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil. 6. School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580, B17, Sao Paulo 05508-000, SP, Brazil. Electronic address: rosariohirata@usp.br.
Abstract
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has a key role in the regulation of plasma low-density lipoprotein (LDL) cholesterol by enhancing the degradation of LDL receptor. Functional variants in PCSK9 have been associated with differences in plasma lipids and may contribute to the variability of the response to cholesterol-lowering drugs. OBJECTIVE: To investigate the influence of PCSK9 variants on plasma lipid profile and response to atorvastatin in Brazilian subjects. METHODS: PCSK9 E670G, I474V, and R46L single nucleotide polymorphisms (SNPs) and plasma lipids were evaluated in 163 hypercholesterolemics (HC) and 171 normolipidemics (NL). HC patients with indication for cholesterol-lowering drug therapy (n = 128) were treated with atorvastatin (10 mg/d/4 wk). PCSK9 SNPs were analyzed by real time polymerase chain reaction. RESULTS: Frequencies of the PCSK9 SNPs were similar between the HC and NL groups. Logistic regression analysis showed a trend of association between PCSK9 E670G and hypercholesterolemia after adjustment for covariates (P = .059). The 670G allele was associated with high basal levels of LDL cholesterol (P = .03) in HC patients using the extreme discordant phenotype method. No association tests were performed for R46L variant because of its very low frequency, whereas the I474V polymorphism and PCSK9 haplotypes were not related to hypercholesterolemia or variability on plasma lipids in both NL and HC groups (P > .05). LDL cholesterol reduction in response to atorvastatin was not influenced by PCSK9 genotypes or haplotypes. CONCLUSIONS: PCSK9 E670G polymorphism but not I474V contributes to the variability on plasma LDL cholesterol levels in hypercholesterolemic subjects. Both PCSK9 variants have no influence on cholesterol-lowering response to atorvastatin.
BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has a key role in the regulation of plasma low-density lipoprotein (LDL) cholesterol by enhancing the degradation of LDL receptor. Functional variants in PCSK9 have been associated with differences in plasma lipids and may contribute to the variability of the response to cholesterol-lowering drugs. OBJECTIVE: To investigate the influence of PCSK9 variants on plasma lipid profile and response to atorvastatin in Brazilian subjects. METHODS:PCSK9E670G, I474V, and R46L single nucleotide polymorphisms (SNPs) and plasma lipids were evaluated in 163 hypercholesterolemics (HC) and 171 normolipidemics (NL). HC patients with indication for cholesterol-lowering drug therapy (n = 128) were treated with atorvastatin (10 mg/d/4 wk). PCSK9 SNPs were analyzed by real time polymerase chain reaction. RESULTS: Frequencies of the PCSK9 SNPs were similar between the HC and NL groups. Logistic regression analysis showed a trend of association between PCSK9E670G and hypercholesterolemia after adjustment for covariates (P = .059). The 670G allele was associated with high basal levels of LDL cholesterol (P = .03) in HC patients using the extreme discordant phenotype method. No association tests were performed for R46L variant because of its very low frequency, whereas the I474V polymorphism and PCSK9 haplotypes were not related to hypercholesterolemia or variability on plasma lipids in both NL and HC groups (P > .05). LDL cholesterol reduction in response to atorvastatin was not influenced by PCSK9 genotypes or haplotypes. CONCLUSIONS:PCSK9E670G polymorphism but not I474V contributes to the variability on plasma LDL cholesterol levels in hypercholesterolemic subjects. Both PCSK9 variants have no influence on cholesterol-lowering response to atorvastatin.
Authors: Q Feng; W Q Wei; C P Chung; R T Levinson; L Bastarache; J C Denny; C M Stein Journal: Pharmacogenomics J Date: 2016-02-23 Impact factor: 3.550
Authors: Tomás Zambrano; Mario Hiroyuki Hirata; Álvaro Cerda; Egidio L Dorea; Gelba A Pinto; Maria C Gusukuma; Marcelo C Bertolami; Luis A Salazar; Rosario Dominguez Crespo Hirata Journal: Int J Clin Exp Med Date: 2015-04-15
Authors: Charles Arama; Issa Diarra; Bourèma Kouriba; Francine Sirois; Olesya Fedoryak; Mahamadou A Thera; Drissa Coulibaly; Kirsten E Lyke; Christopher V Plowe; Michel Chrétien; Ogobara K Doumbo; Majambu Mbikay Journal: PLoS One Date: 2018-02-15 Impact factor: 3.240